Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Post Marketing Surveillance to Observe Safety and Effectiveness of PAXLOVID in Patients, and Who Are at High Risk for Progression to Severe COVID-19

Next Previous
Search
Trial Profile

Post Marketing Surveillance to Observe Safety and Effectiveness of PAXLOVID in Patients, and Who Are at High Risk for Progression to Severe COVID-19

Status: Not yet recruiting
Phase of Trial: Phase IV

Latest Information Update: 29 Jul 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nirmatrelvir+ritonavir (Primary)
  • Indications COVID 2019 infections
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Pfizer

    • Most Recent Events

    • 02 Oct 2023 Planned number of patients changed from 500 to 3000.
    • 02 Oct 2023 Planned End Date changed from 29 May 2029 to 13 Jul 2029.
    • 02 Oct 2023 Planned primary completion date changed from 29 Mar 2029 to 13 Jul 2029.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top